Avastin Growth Cut By Colorectal Cancer Competition, Genentech Says
Executive Summary
Avastin (bevacizumab) utilization in second-line metastatic colorectal cancer is taking a hit from competitor products, Genentech reported during its April 11 first-quarter earnings call
You may also be interested in...
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting
Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says
Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer